Clinical / R&D
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Research & Development
US FDA's first such guidance will focus on hemophilia, commissioner tells Congress.
The UK government has published its life sciences sector deal, which it says will allow the UK to respond to the challenges and opportunities of demographic change and pioneering research and development – although there is no mention of the “Brexit effect.”
A new EMA checklist of “essential considerations” for the successful qualification of novel methodologies covers common issues that have compromised applications for qualification in the past.
Although study was meant to be critical of expedited pathways, it showed that drugs with at least one of the designations experience lower clinical development times.
The EMA says it has taken on board suggestions by the European Ombudsman for changes to its policy on staff declarations of interests, after the Ombudsman cleared the agency of failing to ensure its director general declared all relevant interests when he took up his post in 2011.
The UK government has finally published its Industrial Strategy white paper, which includes a “sector deal” for the life sciences that promises “substantial” private and charitable sector investments.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.